| Year |
Citation |
Score |
| 2024 |
Vince RA, Sun H, Singhal U, Schumacher FR, Trapl E, Rose J, Cullen J, Zaorsky N, Shoag J, Hartman H, Jia AY, Spratt DE, Fritsche LG, Morgan TM. Assessing the Clinical Utility of Published Prostate Cancer Polygenic Risk Scores in a Large Biobank Data Set. European Urology Oncology. PMID 38734542 DOI: 10.1016/j.euo.2024.04.017 |
0.33 |
|
| 2023 |
Wang A, Shen J, Rodriguez AA, Saunders EJ, Chen F, Janivara R, Darst BF, Sheng X, Xu Y, Chou AJ, Benlloch S, Dadaev T, Brook MN, Plym A, Sahimi A, ... ... Cullen J, et al. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nature Genetics. PMID 37945903 DOI: 10.1038/s41588-023-01534-4 |
0.312 |
|
| 2023 |
Chen F, Madduri RK, Rodriguez AA, Darst BF, Chou A, Sheng X, Wang A, Shen J, Saunders EJ, Rhie SK, Bensen JT, Ingles SA, Kittles RA, Strom SS, Rybicki BA, ... ... Cullen J, et al. Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry. European Urology. PMID 36872133 DOI: 10.1016/j.eururo.2023.01.022 |
0.335 |
|
| 2022 |
Basourakos SP, Gulati R, Vince RA, Spratt DE, Lewicki PJ, Hill A, Nyame YA, Cullen J, Markt SC, Barbieri CE, Hu JC, Trapl E, Shoag JE. Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men. Nejm Evidence. 1. PMID 35721307 DOI: 10.1056/evidoa2200031 |
0.329 |
|
| 2022 |
Darst BF, Hughley R, Pfennig A, Hazra U, Fan C, Wan P, Sheng X, Xia L, Andrews C, Chen F, Berndt SI, Kote-Jarai Z, Govindasami K, Bensen JT, Ingles SA, ... ... Cullen J, et al. A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry. European Urology. PMID 35031163 DOI: 10.1016/j.eururo.2021.12.023 |
0.345 |
|
| 2021 |
Kiebish MA, Tekumalla P, Ravipaty S, Dobi A, Srivastava S, Wu W, Patil S, Friss T, Klotz A, Srinivasan A, Cullen J, Rosner IL, Ali A, Laszlo S, Petrovic M, et al. Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia. Scientific Reports. 11: 15052. PMID 34302010 DOI: 10.1038/s41598-021-94438-4 |
0.335 |
|
| 2021 |
Marshall CH, Chen Y, Kuo C, Cullen J, Jiang J, Rosner I, Markowski M, McLeod DG, Trock BJ, Eisenberger MA. Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies. The Journal of Urology. 101097JU000000000000. PMID 34003011 DOI: 10.1097/JU.0000000000001797 |
0.336 |
|
| 2021 |
Zhang KW, Reimers MA, Calaway AC, Fradley MG, Ponsky L, Garcia JA, Cullen J, Baumann BC, Addison D, Campbell CM, Ghosh AK, Lenihan DJ, Desai NR, Weintraub N, Guha A. Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS). The Journal of Urology. 101097JU000000000000. PMID 33872049 DOI: 10.1097/JU.0000000000001785 |
0.301 |
|
| 2021 |
Challa AA, Calaway AC, Cullen J, Garcia J, Desai N, Weintraub NL, Deswal A, Kutty S, Vallakati A, Addison D, Baliga R, Campbell CM, Guha A. Cardiovascular Toxicities of Androgen Deprivation Therapy. Current Treatment Options in Oncology. 22: 47. PMID 33866442 DOI: 10.1007/s11864-021-00846-z |
0.32 |
|
| 2021 |
Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, Schumacher FR, Olama AAA, Benlloch S, Dadaev T, Brook MN, Sahimi A, Hoffmann TJ, Takahashi A, Matsuda K, ... ... Cullen JC, et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics. PMID 33398198 DOI: 10.1038/s41588-020-00748-0 |
0.309 |
|
| 2020 |
Sharad S, Allemang TC, Li H, Nousome D, Ku AT, Whitlock NC, Sowalsky AG, Cullen J, Sesterhenn IA, McLeod DG, Srivastava S, Dobi A. Age and Tumor Differentiation-Associated Gene Expression Based Analysis of Non-Familial Prostate Cancers. Frontiers in Oncology. 10: 584280. PMID 33575208 DOI: 10.3389/fonc.2020.584280 |
0.3 |
|
| 2020 |
Cullen J, Lynch JA, Klein EA, Van Den Eeden SK, Carroll P, Mohler JL, Knezevic D, Farrington T, Lu R. Multicenter Comparison of 17-Gene Genomic Prostate Score as a Predictor of Outcomes in Black and White Men with Clinically Localized Prostate Cancer. The Journal of Urology. 101097JU000000000000. PMID 33493001 DOI: 10.1097/JU.0000000000001484 |
0.342 |
|
| 2020 |
Kohaar I, Chen Y, Banerjee S, Borbiev T, Kuo HC, Ali A, Kagan J, Srivastava S, Dobi A, Sesterhenn IA, Rosner IL, Cullen J, Srivastava S, Petrovics G. A Urine Exosome Gene Expression Panel Distinguishes Between Indolent and Aggressive Prostate Cancers at Biopsy. The Journal of Urology. 101097JU000000000000. PMID 32945736 DOI: 10.1097/Ju.0000000000001374 |
0.349 |
|
| 2020 |
Cullen J, Kuo HC, Shan J, Lu R, Aboushwareb T, Eeden SKVD. The 17-Gene Genomic Prostate Score Test as a Predictor of Outcomes in Men with Unfavorable Intermediate Risk Prostate Cancer. Urology. PMID 32525077 DOI: 10.1016/j.urology.2020.05.045 |
0.329 |
|
| 2020 |
Sharad S, Dillman AA, Sztupinszki ZM, Szallasi Z, Rosner I, Cullen J, Srivastava S, Srinivasan A, Li H. Characterization of unique gene splice variants (isoforms and ) from RNA Seq profiling provides novel insights into prognostic evaluation of prostate cancer. Oncotarget. 11: 362-377. PMID 32064040 DOI: 10.18632/oncotarget.27406 |
0.308 |
|
| 2020 |
Kiebish MA, Cullen J, Mishra P, Ali A, Milliman E, Rodrigues LO, Chen EY, Tolstikov V, Zhang L, Panagopoulos K, Shah P, Chen Y, Petrovics G, Rosner IL, Sesterhenn IA, et al. Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer. Journal of Translational Medicine. 18: 10. PMID 31910880 DOI: 10.1186/S12967-019-02185-Y |
0.335 |
|
| 2020 |
Cullen J, Lynch J, Klein E, Eeden SVD, Carroll P, Mohler J, Lu R, Knezevic D, Lawrence HJ. Mp67-10 A 17-Gene Genomic Assay As A Predictor Of Outcomes In African Americans With Prostate Cancer The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000947.010 |
0.324 |
|
| 2019 |
Mishra P, Kiebish MA, Cullen J, Srinivasan A, Patterson A, Sarangarajan R, Narain NR, Dobi A. Genomic alterations of Tenascin C in highly aggressive prostate cancer: a meta-analysis. Genes & Cancer. 10: 150-159. PMID 31798767 DOI: 10.18632/Genesandcancer.196 |
0.346 |
|
| 2019 |
Yan W, Jamal M, Tan SH, Song Y, Young D, Chen Y, Katta S, Ying K, Ravindranath L, Woodle T, Kohaar I, Cullen J, Kagan J, Srivastava S, Dobi A, et al. Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies as the strongest independent predictor of recurrence. Oncotarget. 10: 6466-6483. PMID 31741711 DOI: 10.18632/Oncotarget.27294 |
0.326 |
|
| 2019 |
Markowski MC, Chen Y, Feng Z, Cullen J, Trock BJ, Suzman D, Antonarakis ES, Paller CJ, Rosner I, Han M, Walsh PC, Partin AW, Eisenberger M. PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. Clinical Genitourinary Cancer. PMID 31530439 DOI: 10.1016/J.Clgc.2019.08.002 |
0.326 |
|
| 2019 |
Lu-Yao G, Nikita N, Keith SW, Nightingale G, Gandhi K, Hegarty SE, Rebbeck TR, Chapman A, Kantoff PW, Cullen J, Gomella L, Kelly WK. Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities. European Urology. PMID 31420248 DOI: 10.1016/J.Eururo.2019.07.031 |
0.318 |
|
| 2019 |
Alexander M, Zhu K, Cullen J, Byrne C, Brown D, Shao S, Rusiecki J. Race and overall survival in men diagnosed with prostate cancer in the Department of Defense Military Health System, 1990-2010. Cancer Causes & Control : Ccc. PMID 30997591 DOI: 10.1007/S10552-019-01163-5 |
0.317 |
|
| 2019 |
Burns JF, Hurwitz LM, Levie KE, Caumont F, Brand TC, Rosner IL, Stroup S, Musser JE, Cullen J, Porter CR. Impact of Subsequent Biopsies on Comprehensive Health Related Quality of Life in Patients With and Without Prostate Cancer. The Journal of Urology. PMID 30676475 DOI: 10.1097/JU.0000000000000024 |
0.321 |
|
| 2019 |
Lu-Yao GL, Nikita N, Keith SW, Banks J, Handley N, Rebbeck T, Cullen J, Domingo-Domenech J, Kelly WK. Racial differences in long-term prostate cancer specific mortality following conservative management for low-risk prostate cancer: A population-based study. Journal of Clinical Oncology. 37: 121-121. DOI: 10.1200/Jco.2019.37.7_Suppl.121 |
0.329 |
|
| 2019 |
Tan S, Martinez A, Rastogi A, Huang W, Banerjee S, Ravindranath L, Young D, Ali A, Kohaar I, Chen Y, Cullen J, Petrovics G, Dobi A, McLeod DG, Kagan J, et al. Abstract 3296: Tumor antigens Fetuin-A and Secreted Protein Acidic and Rich in Cysteine (SPARC) Autoantibodies as diagnostic and prognostic biomarkers in prostate cancer Cancer Research. 79: 3296-3296. DOI: 10.1158/1538-7445.Am2019-3296 |
0.349 |
|
| 2019 |
Kiebish M, Cullen J, Mishra* P, Srinivasan A, Rosner I, McLeod D, Ali A, Rodrigues L, Akmaev V, Sarangarajan R, Narain N, Dobi A, Srivastava S. MP28-15 SERUM BIOMARKERS FOR PROGNOSIS OF DISEASE PROGRESSION IN PROSTATE CANCER USING MULTI-OMICS Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555720.04962.3D |
0.312 |
|
| 2019 |
Kohaar I, Banerjee S, Chen Y, Ali A, Kagan J, Srivastava S, Cullen J, Rosner I, Srivastava S, Petrovics G. Pd11-09 Development Of Race Specific Urine Based Gene Expression Panels For Prostate Cancer The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555365.82349.11 |
0.325 |
|
| 2019 |
Marshall CH, Chen Y, Cullen J, Rosner I, Markowski M, Trock B, Eisenberger M. Overall survival (OS) and metastasis-free survival (MFS) in men with biochemically relapsed (BCR) prostate cancer after radical prostatectomy (RP) managed with deferred androgen deprivation treatment (ADT): A combined Johns Hopkins and CPDR study Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz248.009 |
0.306 |
|
| 2018 |
Salter CA, Cullen J, Kuo C, Chen Y, Hurwitz L, Metwalli AR, Dimitrakoff J, Rosner IL. Alkaline Phosphatase Kinetics Predict Metastasis among Prostate Cancer Patients Who Experience Relapse following Radical Prostatectomy. Biomed Research International. 2018: 4727089. PMID 30050933 DOI: 10.1155/2018/4727089 |
0.314 |
|
| 2018 |
Cullen J, Gesztes W, Williams G, Burke A, Young D, Mygatt J, Chen Y, Kuo H, Srivastava S, Rosner IL, Sesterhenn I. Tumor location and symmetry on prostate cancer progression in a racially diverse military cohort. Journal of Clinical Oncology. 36: e17065-e17065. DOI: 10.1200/JCO.2018.36.15_SUPPL.E17065 |
0.321 |
|
| 2018 |
Dobi A, Petrovics G, Li H, Young D, Chen Y, Kagan J, Srivastava S, Ebner R, Rosner IL, Cullen J, Freedman ML, Sesterhenn IA, Szallasi Z, Srivastava S. Abstract PR01: Distinct genomic alterations in prostate cancer of African American men Cancer Epidemiology, Biomarkers & Prevention. 27. DOI: 10.1158/1538-7755.Disp17-Pr01 |
0.3 |
|
| 2018 |
Kiebish MA, Tekmulla P, Ravipaty S, Wu W, Friss T, Liao C, Klotz A, Andreazi J, Hutchins E, Dobi A, Srivastava S, Cullen J, Ali A, Freedland S, Griffin K, et al. Abstract LB-219: Clinical utility of a serum protein biomarker panel (FLNA, KRT19) in stratification of prostate cancer from benign prostate hyperplasia patients Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-219 |
0.335 |
|
| 2018 |
Kiebish M, Cullen J, Ali A, Rodrigues LO, Chen EY, Milliman E, Xang L, Tolstikov V, Gao F, Panagopoulos K, Garren J, Chen Y, Petrovics G, Rosner IL, Sesterhenn IA, et al. Abstract 3595: A panel of serum proteins, metabolite and lipid for prognosing prostate cancer progression Cancer Research. 78: 3595-3595. DOI: 10.1158/1538-7445.Am2018-3595 |
0.306 |
|
| 2018 |
Cullen J, Lawrence H, Chen Y, Lu R, Srivastava S, Rosner I, Brand T, Sesterhenn I. Prediction of prostate cancer gleason score upgrading from biopsy to radical prostatectomy (RP) using a validated 17-gene panel assay Annals of Oncology. 29: viii293. DOI: 10.1093/ANNONC/MDY284.046 |
0.301 |
|
| 2018 |
Mygatt J, Cullen J, Kuo H, Chen Y, Burke A, Srivastava S, Rice K, Rosner I, Sesterhenn I. MP34-03 DO ANTERIOR TUMOR LOCATION AND RACE PREDICT BIOCHEMICAL OUTCOMES FOR LOW RISK PROSTATE CANCER PATIENTS? Journal of Urology. 199. DOI: 10.1016/J.JURO.2018.02.1095 |
0.307 |
|
| 2018 |
Caumont F, Hurwitz L, Levie K, Burns J, Brand T, Rosner I, Stroup S, Sterbis J, Cullen J, Porter C. MP34-02 THE IMPACT OF RACE AND AGE IN FAILURE AND PROGRESSION IN PATIENTS UNDER ACTIVE SURVEILLANCE FOR PROSTATE CANCER. RESULTS FROM A LARGE PROSPECTIVE DATABASE Journal of Urology. 199. DOI: 10.1016/J.JURO.2018.02.1094 |
0.32 |
|
| 2017 |
Hurwitz LM, Cullen J. Reply to Prostate cancer multidisciplinary clinic and decisional regret: Looking for a longer follow-up. Cancer. PMID 28976542 DOI: 10.1002/cncr.31053 |
0.328 |
|
| 2017 |
Cullen J, Young D, Chen Y, Degon M, Farrell J, Sedarsky J, Baptiste W, Rosen P, Tolstikov V, Kiebish M, Kagan J, Srivastava S, Kuo HC, Moncur JT, Rosner IL, et al. Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort. European Urology Focus. PMID 28753864 DOI: 10.1016/J.Euf.2017.02.016 |
0.304 |
|
| 2017 |
Hurwitz LM, Cullen J, Kim DJ, Elsamanoudi S, Hudak J, Colston M, Travis J, Kuo HC, Rice KR, Porter CR, Rosner IL. Longitudinal regret after treatment for low- and intermediate-risk prostate cancer. Cancer. PMID 28678408 DOI: 10.1002/cncr.30841 |
0.337 |
|
| 2017 |
Markowski MC, Suzman D, Chen Y, Trock BJ, Cullen J, Feng Z, Antonarakis ES, Paller CJ, Han M, Partin AW, Eisenberger MA. PSA doubling time (PSADT) and proximal PSA value predict metastasis-free survival (MFS) in men with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy (RP). Journal of Clinical Oncology. 35: 5075-5075. DOI: 10.1200/Jco.2017.35.15_Suppl.5075 |
0.313 |
|
| 2017 |
Febbo PG, Crager M, Burke E, Lawrence HJ, Cullen J, Klein EA. Association of risk of clinical recurrence (CR) and prostate cancer death (PCD) with a 17-gene genomic prostate score (GPS) value <20. Journal of Clinical Oncology. 35: 5074-5074. DOI: 10.1200/Jco.2017.35.15_Suppl.5074 |
0.315 |
|
| 2017 |
Cullen J, Kuo H, Hurwitz L, Rosner IL, Rebbeck T, D'Amico AV, Lu-Yao GL. Predictors of post-surgical race-specific prostate cancer progression. Journal of Clinical Oncology. 35: 5048-5048. DOI: 10.1200/Jco.2017.35.15_Suppl.5048 |
0.339 |
|
| 2017 |
Kiebish MA, Cullen J, Dobi A, Ali A, Rodrigues LO, Sun Y, Pawar A, Dalvi A, Young D, Vishnudas VK, Sedarsky J, Petrovics G, Chen E, Akmaev V, Rosner IL, et al. Abstract 4645: A serum multiomics signature for enhancing prostate cancer diagnosis and prognosis Cancer Research. 77: 4645-4645. DOI: 10.1158/1538-7445.Am2017-4645 |
0.315 |
|
| 2017 |
Salter C, Cullen J, Rosner I, Kuo H(, Metwalli A. MP14-18 ALKALINE PHOSPHATASE VELOCITY PREDICTS METASTASIS AMONG PROSTATE CANCER PATIENTS WHO EXPERIENCE BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY Journal of Urology. 197. DOI: 10.1016/j.juro.2017.02.482 |
0.301 |
|
| 2017 |
Smith C, Skinner W, Rosner I, Kuo C, Chen Y, Stroup S, Brand T, Sterbis J, Porter C, Cullen J. Racial Disparities in Prostate Cancer Outcomes Following Radiation for Men Diagnosed and Treated in an Equal Access Military Healthcare System International Journal of Radiation Oncology*Biology*Physics. 99: S207. DOI: 10.1016/J.IJROBP.2017.06.513 |
0.314 |
|
| 2016 |
Pham KN, Cullen J, Hurwitz LM, Wolff EM, Levie KE, Odem-Davis K, Banerji JS, Rosner IL, Brand TC, L'Esperance JO, Sterbis JR, Porter CR. Prospective Quality of Life in Men Choosing Active Surveillance Compared to Those Biopsied but not Diagnosed with Prostate Cancer. The Journal of Urology. PMID 26976206 DOI: 10.1016/j.juro.2016.02.2972 |
0.312 |
|
| 2016 |
Suzman DL, Cullen J, Trock BJ, Chen Y, Rosner IL, Feng Z, Antonarakis ES, Han M, Partin AW, Hurwitz L, Kuo H, McLeod DG, Eisenberger MA. PSA doubling time (PSADT) ≤6 months to identify a subgroup of men with biochemically-recurrent prostate cancer (BRPC) after prostatectomy (RP) at highest risk of distant metastasis (dMET). Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E16587 |
0.312 |
|
| 2016 |
Lee J, Jamal M, Yan W, young D, Song Y, Chen Y, Katta S, Ravindranath L, Srinivasan A, Cullen J, Kagan J, Srivastava S, Dobi A, Rosner IL, McLeod DG, et al. Abstract A35: Increased expression of PCGEM1 lncRNA in prostate cancer of African American men Cancer Research. 76. DOI: 10.1158/1538-7445.Nonrna15-A35 |
0.31 |
|
| 2016 |
Cullen J, Young D, Chen Y, Degon MS, Baptiste W, Farrell JS, Sedarsky JS, Kuo H, Kagan J, Srivastava S, Rosner IL, Petrovics G, Dobi A, McLeod DG, Srivastava S, et al. Abstract 3448: ERG-negative index tumor status combined with obesity predict prostate cancer progression in Caucasian American prostate cancer patients Cancer Research. 76: 3448-3448. DOI: 10.1158/1538-7445.Am2016-3448 |
0.319 |
|
| 2015 |
Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, Ali A, Chen Y, Knezevic D, Maddala T, Lawrence HJ, Febbo PG, Srivastava S, Sesterhenn IA, McLeod DG. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer. European Urology. 68: 123-31. PMID 25465337 DOI: 10.1016/J.Eururo.2014.11.030 |
0.342 |
|
| 2015 |
Cullen J, Rosner IL, Brand TC, Ali A, Chen Y, Zhang N, Tsiatis AC, Knezevic D, Maddala T, Lawrence HJ, Febbo PG, Srivastava S, Sesterhenn I, Mcleod DG. The association of a 17-gene genomic prostate score with adverse surgical pathology and recurrence following surgery for localized prostate cancer (PCa): A comparison of African American and Caucasian patients. Journal of Clinical Oncology. 33: 86-86. DOI: 10.1200/Jco.2015.33.7_Suppl.86 |
0.326 |
|
| 2015 |
Dobi A, Degon M, Farrell J, Baptiste W, Young D, Chen Y, Petrovics G, Cullen J, Kagan J, Srivastava S, Rosner I, McLeod DG, Srivastava S, Sesterhenn I. Abstract 5277: ERG-based stratification of prostate cancer highlights ethnicity associated biological differences Cancer Research. 75: 5277-5277. DOI: 10.1158/1538-7445.Am2015-5277 |
0.3 |
|
| 2015 |
Lee J, Yan W, Young D, Song Y, Chen Y, Katta S, Mohamed A, Ravindranath L, Srinivasan A, Cullen J, Kagan J, Srivastava S, Dobi A, Rosner I, McLeod DG, et al. Abstract 2016: Evaluation of prostate cancer biomarkers and therapeutic targets in FFPE specimens using the NanoString platform Cancer Research. 75: 2016-2016. DOI: 10.1158/1538-7445.Am2015-2016 |
0.311 |
|
| 2015 |
Cullen J, Sesterhenn I, Klein E, Mohler J, Carroll P, Cooperberg M, Zhang N, Maddala T, Knezevic D, Tsiatis A, Lawrence HJ, Febbo P. Mp1-05 A Multi-Center Comparison Of A 17-Gene Genomic Prostate Score (Gps) As A Predictor Of Outcomes In African-American (Aa) And Caucasian (Ca) Men With Clinically Localized Prostate Cancer (Pca) The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.168 |
0.304 |
|
| 2014 |
Farrell J, Young D, Chen Y, Cullen J, Rosner IL, Kagan J, Srivastava S, McLEOD DG, Sesterhenn IA, Srivastava S, Petrovics G. Predominance of ERG-negative high-grade prostate cancers in African American men. Molecular and Clinical Oncology. 2: 982-986. PMID 25279185 DOI: 10.3892/mco.2014.378 |
0.317 |
|
| 2014 |
Dobi A, Rosen P, Farrell J, Degon M, Young D, Srivastava S, Kagan J, Petrovics G, Cullen J, McLeod DG, Sesterhenn IA, Srivastava S. Abstract C18: ERG-focused evaluations of prostate cancer of African American men and its potential impact on utility in biomarker development and in enhanced personalized medicine Cancer Epidemiology, Biomarkers & Prevention. 23. DOI: 10.1158/1538-7755.Disp13-C18 |
0.362 |
|
| 2014 |
Dobi A, Chen Y, Ali A, Young D, Rosen P, Farrell J, Degon M, Srivastava S, Kagan J, Lee J, Cullen J, Petrovics G, McLeod DG, Sesterhenn IA, Srivastava S. Abstract 1859: Potential impact on the biology and biomarker utility of ERG-typing in the context of ethnic differences of prostate cancer Cancer Research. 74: 1859-1859. DOI: 10.1158/1538-7445.Am2014-1859 |
0.314 |
|
| 2014 |
Pham K, Jeldres C, Johnston R, Cullen J, Odem-Davis K, Wolff E, Levie K, Hurwitz L, Porter C. Mp15-07 Health-Related Quality Of Life For Men With Low Risk Prostate Cancer Managed With Active Surveillance Compared To A Cancer-Screening Cohort Without Prostate Cancer The Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.560 |
0.337 |
|
| 2014 |
Chen Y, Cullen J, Ali A, McLeod DG, Srivastava S. MP78-08 RACIAL/ETHNIC PATTERNS IN THE PERFORMANCE OF MULTIPLEX URINE ERG AND PCA3 FOR PROSTATE CANCER DETECTION Journal of Urology. 191. DOI: 10.1016/j.juro.2014.02.2491 |
0.313 |
|
| 2014 |
Farrell J, Young D, Degon M, Srivastava S, Kagan J, Cullen J, Petrovics G, Rosner I, McLeod DG, Sesterhenn IA, Srivastava S. MP41-01 HIGHER GRADE PROSTATE CANCER STRATIFICATION BY ERG ONCOPROTEIN AND SPINK1 EXPRESSION IN CAUCASIAN AMERICAN AND AFRICAN AMERICAN MEN Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1218 |
0.312 |
|
| 2013 |
Rice KR, Colombo ML, Wingate J, Chen Y, Cullen J, McLeod DG, Brassell SA. Low risk prostate cancer in men ≥ 70 years old: to treat or not to treat. Urologic Oncology. 31: 755-60. PMID 21872499 DOI: 10.1016/j.urolonc.2011.07.004 |
0.325 |
|
| 2013 |
Barrisford GW, Degon M, Cullen J, Chen Y, McLeod DG, L'Esperance JO, Brand T, Porter C, Sterbis J, Rosner IL. 224 ACTIVE SURVEILLANCE FOR YOUNG PROSTATE CANCER PATIENTS Journal of Urology. 189. DOI: 10.1016/J.JURO.2013.02.1604 |
0.328 |
|
| 2012 |
Rosen P, Pfister D, Young D, Petrovics G, Chen Y, Cullen J, Böhm D, Perner S, Dobi A, McLeod DG, Sesterhenn IA, Srivastava S. Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. Urology. 80: 749-53. PMID 22950997 DOI: 10.1016/j.urology.2012.07.001 |
0.31 |
|
| 2012 |
Cullen J, Elsamanoudi S, Brassell SA, Chen Y, Colombo M, Srivastava A, McLeod DG. The burden of prostate cancer in Asian nations. Journal of Carcinogenesis. 11: 7. PMID 22529743 DOI: 10.4103/1477-3163.94025 |
0.33 |
|
| 2012 |
Tausch T, Cullen J, Chen Y, Brand T. 335 “VERY LOW RISK” APPEARS TO BE A VALID NOVEL RISK STRATIFICATION FOR LOCALIZED PROSTATE CANCER Journal of Urology. 187. DOI: 10.1016/J.JURO.2012.02.396 |
0.317 |
|
| 2011 |
Brassell SA, Rice KR, Parker PM, Chen Y, Farrell JS, Cullen J, McLeod DG. Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes. The Journal of Urology. 185: 132-7. PMID 21074211 DOI: 10.1016/j.juro.2010.09.014 |
0.324 |
|
| 2011 |
Lee G, Russell D, Parker P, Sesterhenn I, Cullen J, Furusato B, Dobi A, McLeod D, Srivastava S, Moncur J. UP-02.194 Improved Detection of Prostate Cancer by the Combined Application of ERG and AMACR Immunohistochemical Stainings in Prostate Biopsy Specimens Urology. 78: S328-S329. DOI: 10.1016/J.UROLOGY.2011.07.1012 |
0.315 |
|
| 2008 |
Hu Y, Dobi A, Sreenath T, Cook C, Tadase AY, Ravindranath L, Cullen J, Furusato B, Chen Y, Thangapazham RL, Mohamed A, Sun C, Sesterhenn IA, McLeod DG, Petrovics G, et al. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4719-25. PMID 18676740 DOI: 10.1158/1078-0432.CCR-08-0531 |
0.328 |
|
| 2008 |
Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality. Urology. 71: 136-40. PMID 18242382 DOI: 10.1016/J.Urology.2007.08.028 |
0.329 |
|
| 2008 |
Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG, Dobi A, Srivastava S, Petrovics G, Sesterhenn IA. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 21: 67-75. PMID 18065961 DOI: 10.1038/modpathol.3800981 |
0.329 |
|
| 2007 |
Punglia RS, Cullen J, McLeod DG, Chen Y, D'Amico AV. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer. Cancer. 110: 1973-8. PMID 17886252 DOI: 10.1002/cncr.23014 |
0.33 |
|
| 2007 |
Shaheduzzaman S, Vishwanath A, Furusato B, Cullen J, Chen Y, Bañez L, Nau M, Ravindranath L, Kim KH, Mohammed A, Chen Y, Ehrich M, Srikantan V, Sesterhenn IA, McLeod D, et al. Silencing of Lactotransferrin expression by methylation in prostate cancer progression. Cancer Biology & Therapy. 6: 1088-95. PMID 17568188 |
0.315 |
|
| 2007 |
D'Amico AV, McLeod DG, Carroll PR, Cullen J, Chen MH. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality. Cancer. 109: 1290-5. PMID 17315162 DOI: 10.1002/Cncr.22550 |
0.34 |
|
| 2007 |
Wright JL, Cullen J, McLeod DG, Porter CR. 1408: The Importance of Prostate Cancer Tumor Volume in Men with Pathologically Organ Confined Disease Journal of Urology. 177: 464-465. DOI: 10.1016/s0022-5347(18)31609-4 |
0.3 |
|
| 2007 |
Wright JL, Cullen J, McLeod DG, Porter CR. 1402: Predicting Biochemical Failure in Men with Low Volume (< 0.5CC) Prostate Cancer Treated by Radical Prostatectomy Journal of Urology. 177: 461-462. DOI: 10.1016/S0022-5347(18)31603-3 |
0.31 |
|
| 2007 |
Shaheduzzaman S, Vishwanath A, Furusato B, Cullen J, Chen Y, Bañez LL, Nau M, Ravindranath L, Kim K, Mohamed A, Chen Y, Ehrich M, Srikantan V, Sesterhenn IA, McLeod DG, et al. 669: Effects and Mechanisms of Frequent Downregulation of Lactotransferrin (LTF) in Prostate Cancer The Journal of Urology. 177: 224-225. DOI: 10.1016/S0022-5347(18)30909-1 |
0.328 |
|
| 2007 |
Gao C, Petrovics G, Cullen J, Furusato B, Ravindranath L, Cook C, Chen Y, Dobi A, Sesterhenn IA, McLeod DG, Srivastava S. 280: Quantitative Features of a Common TMPRSS2-ERG Fusion Transcript in Prostate Cancer Journal of Urology. 177: 94-94. DOI: 10.1016/S0022-5347(18)30545-7 |
0.305 |
|
| 2006 |
D’Amico AV, Cullen J, Chen Y, McLeod DG. Prostate-specific antigen velocity and the odds of detecting gleason 8 to 10 prostate cancer at biopsy Journal of Clinical Oncology. 24: 4567-4567. DOI: 10.1200/jco.2006.24.18_suppl.4567 |
0.351 |
|
| 2006 |
D’Amico AV, Cullen J, Chen Y, McLeod DG. 523: Prostate-Specific Antigen Velocity and the Odds of Identifying Prostate Cancer at Biopsy Journal of Urology. 175: 169-170. DOI: 10.1016/s0022-5347(18)32769-1 |
0.316 |
|
| 2006 |
Bañez LL, Shaheduzzaman S, Vishwanath A, Furusato B, Nau M, Ravindranath L, Chen Y, Chen Y, Cullen J, Sesterhenn IA, Vahey M, McLeod DG, Petrovics G, Srikantan V, Srivastava S. 435: Lactotransferrin: A Frequent Expression Down-Regulation in Prostate Cancer The Journal of Urology. 175: 141-141. DOI: 10.1016/S0022-5347(18)32691-0 |
0.318 |
|
| Show low-probability matches. |